Resistant Pseudomonas Aeruginosa Infections Drugs Market
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size, Share & Trends Analysis Report by Type (Semi-Synthetic Penicillin, Cephalosporin, and Lactam Drugs), and by Application (Hospital and Clinic, and Home Care) Forecast 2022-2028
The global resistant pseudomonas aeruginosa infections drugs market is anticipated to grow at a significant CAGR of 4.5% during the forecast period. The gram-negative bacteria Pseudomonas aeruginosa is a frequently encapsulated bacillus that can cause sickness in humans. Pseudomonas aeruginosa is a multidrug-resistant organism renowned for its widespread distribution, naturally advanced antibiotic resistance mechanism, and links to significant illnesses such as nosocomial infections like ventilator-related pneumonia and septic syndromes. Development of products that encourage an increase in the number of Pseudomonas aeruginosa-infected people, an increase in the incidence of Pseudomonas aeruginosa-related diseases such as pneumonia, cystic fibrosis, and urinary tract infections, and an increase in antibiotic resistance. Key factors that drive the growth of pseudomonas aeruginosa include an increase in the Pseudomonas aeruginosa infection market and an increase in R&D activity. For instance, Teva Pharmaceuticals released generic Erythromycin tablets in 250 mg and 500 mg dosages in May 2021. Teva generic Erythromycin tablets are used to treat a variety of bacterial infections and to prevent the onset or recurrence of rheumatic fever in people who are allergic to penicillin.
Impact of COVID-19 Pandemic on Global Resistant Pseudomonas Aeruginosa Infections Drugs Market
The COVID-19 pandemic had a favorable impact on the pharmaceutical sector. It has an impact on the market for pseudomonas aeruginosa treatment. COVID-19 individuals infected with pseudomonas auregeniosa are treated with "oral ciprofloxacin" medication products. Antibiotic use in patients is reduced as a result of expanded therapy for P aeruginosa and methicillin-resistant S aureus. A guideline for the management of individuals with community-acquired pneumonia and COVID-19 has been published by the "America Thoracic Society and Infection Disease." These factors contribute to the market's expansion. Segmental Outlook
The global resistant pseudomonas aeruginosa infections drugs market is segmented based on the type and application. Based on the type, the market is segmented into semi-synthetic penicillin, cephalosporin, and lactam drugs. Based on the application, the market is sub-segmented into the hospital and clinic, and home care. The market for pseudomonas aeruginosa infection treatment is projected to be dominated by clinics. Aminoglycosides are antibiotics with a broad spectrum of activity that are used in clinics to treat life-threatening illnesses. They belong to the antibiotic class of antibiotics that are used to treat infections caused by aerobic gram-negative bacteria.
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type, 2021 (%)
The Semi-Synthetic Penicillin Segment is Anticipated to Hold a Prominent Share in the Global Resistant Pseudomonas Aeruginosa Infections Drugs Market
During the forecast period, the semi-synthetic penicillin antibiotic is anticipated to hold a prominent share in the market. This is the most utilised therapy for delivering medications that have been carefully chosen to target specific molecules due to multidrug resistance in pseudomonas aeruginosa. This indicates that combination therapy has a larger market share in the treatment of pseudomonas aeruginosa infections. For instance, Allergan announced in February 2018 that the FDA had approved AVYCAZ (Ceftazidime and avibactam) for the treatment of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Regional Outlooks
The global resistant pseudomonas aeruginosa infections drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin AmericaThe Asia-Pacific regional Resistant Pseudomonas Aeruginosa Infections Drugs market is expected to hold prominent market share due to increasing number of patients and the presence of several key market players.
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Growth, by Region 2022-2028
The Asia-Pacific Region is Estimated to Hold the Major Share in the Global Resistant Pseudomonas Aeruginosa Infections Drugs Market
The Asia-pacific region is estimated to hold the major share in the global resistant pseudomonas aeruginosa infections drugs market. The growth of the resistant pseudomonas aeruginosa infections drugs market in the Asia-Pacific is being fueled by green healthcare systems and tremendous compensation regulations from each public and business medical insurance provider. In addition, the rising number of patients seeking treatment, higher healthcare spending, and the rising prevalence of hospital-acquired disease all contribute to Asia-Pacific dominance. For instance, according to Elsevier Inc., bacterial antimicrobial resistance caused an estimated 4.95 million mortalities in 2019.
Market Players Outlook
The major companies serving the global resistant pseudomonas aeruginosa infections drugs market include AbbVie Inc., Bristol Myers Squibb Co., Biolytics Pharma, ContraFect Corp., Novartis AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in October 2018, the Development and evaluation of risk scores for carbapenem and overall ?-lactam resistance in adult inpatients with Pseudomonas aeruginosa infection
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global resistant pseudomonas aeruginosa infections drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Resistant Pseudomonas Aeruginosa Infections Drugs Market
- Recovery Scenario of Global Resistant Pseudomonas Aeruginosa Infections Drugs Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. AbbVie Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Bristol Myers Squibb Co.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Biolytics Pharma
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. ContraFect Corp.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Novartis AG
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market by Type
4.1.1. Semi-Synthetic Penicillin
4.1.2. Cephalosporin
4.1.3. Lactam Drugs
4.2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market by Application
4.2.1. Hospital and Clinic
4.2.2. Home Care
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AstraZeneca plc
6.2. Inhibrx LP
6.3. Johnson & Johnson
6.4. LegoChem Biosciences Inc.
6.5. Lupin Pharmaceuticals, Inc.
6.6. Melinta Therapeutics Inc.
6.7. Merck & Co., Inc.
6.8. Pfizer, Inc.
6.9. Shionogi & Co. Ltd.
6.10. Teva Pharmaceutical Industries Ltd.
1. GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL SEMI-SYNTHETIC PENICILLIN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL CEPHALOSPORIN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL LACTAM DRUGS RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
6. GLOBAL HOSPITAL AND CLINIC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL HOME CARE RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
9. NORTH AMERICAN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
11. NORTH AMERICAN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
12. EUROPEAN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. EUROPEAN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
14. EUROPEAN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
15. ASIA-PACIFIC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
18. REST OF THE WORLD RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. REST OF THE WORLD RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
20. REST OF THE WORLD RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET, 2021-2028 (%)
4. GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL SEMI-SYNTHETIC PENICILLIN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL CEPHALOSPORIN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL LACTAM DRUGS RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
9. GLOBAL HOSPITAL AND CLINIC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL HOME CARE RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. US RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
13. CANADA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
14. UK RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
15. FRANCE RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
16. GERMANY RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
17. ITALY RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
18. SPAIN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
19. REST OF EUROPE RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
20. INDIA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
21. CHINA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
22. JAPAN RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
23. SOUTH KOREA RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF ASIA-PACIFIC RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF THE WORLD RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS DRUGS MARKET SIZE, 2021-2028 ($ MILLION)
